Pramipexole ER uptake to be inhibited by availability of generic version

Links shared publicly online about this topic.

1,272
total visits

Pramipexole ER uptake to be inhibited by availability of generic version

HealthLeaders-InterStudy and Fingertip Formulary find that the uptake of Boehringer Ingelheim's pramipexole ER, the once-daily formulation of its market leading dopamine agonist Mirapex that was approved earlier this month, will be inhibited by competition from generic pramipexole which became available earlier this year.

View full resource at news-medical.net

Tags: Parkinson's Disease, Parkinson's Disease Medication, Neuropathic Pain Medication, Disease and Condition, Medicare, Sifrol, Mirapex, Boehringer Ingelheim